Navigation Links
Odyssey Thera Announces Collaboration With Mitsubishi Tanabe Pharma Corporation, and Issuance of Core Patent in Japan
Date:5/15/2009

SAN RAMON, Calif., May 15 /PRNewswire/ -- Odyssey Thera, Inc. announced today the initiation of a collaboration with leading Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation. The alliance involves the analysis of drug candidates from a number of Mitsubishi Tanabe preclinical programs. Odyssey also announced the issuance of Japanese patent number JP 4262778, entitled "Protein fragment complementation assays for the detection of biological or drug interactions."

"We look forward to applying our patented human cell analysis technologies and proprietary drug profiling strategies to enhance Mitsubishi Tanabe's promising drug discovery programs," said Dr. John Westwick, President and CEO of Odyssey Thera. "Our partnership with Mitsubishi Tanabe, and the issuance of our Japanese patent, reflect our objective of making our unique knowledge base and enabling technologies available to quality partners around the globe."

Odyssey Thera will apply its patented Protein-fragment Complementation Assay (PCA), proprietary High Context Screening infrastructure, unique institutional knowledge, and state-of-the-art data analysis strategies in the collaboration to yield valuable insights related to drug selectivity, safety, and mechanisms of action. Financial terms of the collaboration were not disclosed.

About Odyssey Thera

Odyssey Thera, Inc. is a drug discovery company committed to identifying novel drug candidates for oncology and other chronic diseases. Odyssey Thera's live cell, pathway-based approach centers on its proprietary Protein-fragment Complementation Assay (PCA) technology and unique High Context Screening platform. Using these capabilities, Odyssey scientists have gained unique knowledge regarding cellular pathways and drug mechanisms. Odyssey's highly experienced team is using these capabilities to mine cellular systems and discover novel drug candidates for internal programs, and in partnerships with top pharmaceutical companies. To learn more about Odyssey Thera, please visit www.odysseythera.com.


'/>"/>
SOURCE Odyssey Thera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
2. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
3. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
4. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
5. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
6. Odyssey Thera Granted U.S. Patent for Animal Imaging
7. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Orexigen(R) Therapeutics to Present at Upcoming Meetings
10. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
11. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):